AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
argenx SE
Video analysis: ARGNF
All videosNo video analysis for this stock yet. Request one from our team.
News: ARGNF
BenchSci Announces Two-Year Enterprise Agreement with argenx to Advance AI-Driven Preclinical Drug Discovery
TORONTO--(BUSINESS WIRE)--BenchSci, a leading provider of AI software for biopharma research and development, today announced a two-year enterprise agreement with argenx, a global immunology innovation company, to deploy EMET, BenchSci's agentic research environment for preclinical drug discovery, within the organization. Selected through a competitive evaluation led by argenx's own scientists, the agreement represents a significant milestone in BenchSci's expansion across European biopharma. U.
Argenx to Buy Forte Biosciences for $2.2 Billion
The deal to acquire the Nasdaq-listed Forte represents a 41% premium to its closing price on Friday.
Argenx to buy Forte Biosciences for about $2.2 billion
Belgian-Dutch immunology company argenx will buy Forte Biosciences to add experimental autoimmune drug FB102 to its portfolio, the company said on Monday.
Argenx's Vyvgart sales jump in second quarter
Belgian-Dutch immunology company argenx said on Thursday global sales of its lead drug Vyvgart jumped in the second quarter of 2026 from a year earlier.